Quantcast

Latest MiR-122 Stories

2015-04-25 12:22:54

-RG-101 Achieves Sustained HCV Viral Suppression with Favorable Safety and Tolerability- LA JOLLA, Calif., April 25, 2015 /PRNewswire/ -- Regulus Therapeutics Inc.

2015-04-02 23:01:01

Researchers at UC Davis have unraveled some of these relationships, identifying several interactions that directly impact liver and colon cancer. SACRAMENTO,

2015-02-09 08:30:48

-Extended Follow-Up Shows 4/14 Patients Treated with a Single SC Dose of 2 mg/kg of RG-101 are Target Not Detected at Day 85 - LA JOLLA, Calif., Feb.

2015-01-22 20:21:27

DALLAS, January 23, 2015 /PRNewswire/ -- LifeScienceIndustryResearch.com adds Hepatitis C Global Clinical Trials Review, H2, 2014 as well as Hepatitis C Market & Forecast,

2015-01-08 08:28:33

Accelerates RG-101 for HCV with Dual-Track Clinical Development Strategy; Top-Line, Single Dose, 4 mg/kg Results as Well as 2mg/kg Extended Follow Up Results from Ongoing Study to be Reported in Early

2014-11-18 23:03:50

Nature Communications paper offers pivotal new information about how the virus interacts with and evades therapeutics, as well as new clues to its role in cancer development. New

2014-10-22 08:31:10

- Interim Results from Ongoing Study Demonstrate Human Proof-of-Concept and Underscore the Value of Regulus' microRNA Platform - LA JOLLA, Calif., Oct.

2014-10-14 08:32:24

-New Preclinical Results Increase Mechanistic Understanding of Targeting miR-103/107 for Metabolic Disorders and miR-21 for Renal Dysfunction in Alport Syndrome Patients- LA JOLLA, Calif.,

2014-08-06 16:29:29

- 'Clinical Map Initiative' On Track; Human Proof of Concept Results for RG-101 and Nomination of Third Clinical Candidate Expected by YE 2014 - LA JOLLA, Calif., Aug.

2014-06-25 08:30:45

- New Method of Use Claims Strengthen Patent Estate Covering microRNA-122 Inhibitors for the Treatment of HCV Infection - LA JOLLA, Calif., June 25, 2014 /PRNewswire/ --


Word of the Day
shotta
  • An armed gangster.
The word 'shotta' is an alteration of 'shooter'.